S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with
advanced soft tissue sarcomas.